Slide 1: Second Quarter 2008 Webcast
Exhibit 99.1 Second Quarter 2008 Webcast July 24, 2008
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements contained in this presentation that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially. This presentation is being made on July 24, 2008, and Alcon does not undertake
Slide 3: Business Overview
Business Overview Cary Rayment Chairman, President & CEO 3
Slide 4: Second Quarter Sales Highlights
Second Quarter Sales Highlights 2nd Qtr June 2008 YTD $1,900 $3,600 . 9 % 11.2% . 1 % 10.3% +17 cy* +17 cy* $1,800 + $3,400 + e n e n Curr Curr $1,700 t $3,200 t tan $1,735.2 stan ns Co n $3,271.6 Co $1,600 $3,000 $1,500 $2,800 $1,471.5 $2,794.2 $1,400 $2,600 $1,300 $2,400 Q2 2007 Q2 2008 June YTD 2
Slide 5: Q2 2008 Geographic Sales and Growth
Q2 2008 Geographic Sales and Growth Q2 2008 Sales by Geography $305.5 Reported: +29.5% Emerging Constant Currency*: +18.9% Markets $787.9 17.6% Reported: +7.0% U.S. 45.4% Developed International 37.0% $641.8 Reported: +28.5% Constant Currency*: 13.7% (dollars in millions) * Constant currency sales g
Slide 6: Pharmaceutical Sales
Pharmaceutical Sales Q2 2008 Sales by Product Line 2nd Qtr $850 . 6 % 12.1% +17 cy* $800 + e n Consumer Curr $750 t $221.4 stan n Pharma Co $745.1 $700 $745.1 42.9% $650 Surgical $768.7 $600 $633.8 $550 $500 Q2 2007 Q2 2008 * Constant currency sales growth is a non-GAAP measure presented to give inv
Slide 7: Gaining Market Share in Pharmaceuticals
Gaining Market Share in Pharmaceuticals Global US RX Growth March YTD May 2008 Brand Market Brand Market TRAVATAN® Family 23.4% 8.7% 12.7% -0.3% Azopt® 8.5% 5.5% 19.1% 5.7% Vigamox® * 26.0% 8.0% -1.0% -3.4% Tobradex® 0.7% 7.0% -6.7% -3.6% Nevanac® 44.4% 2.3% 22.5% 10.9% Patanol® + PatadayTM 25.4% 1.
Slide 8: TRAVATAN Global Market Success
TRAVATAN® Global Market Success Global Glaucoma Market Share by Product The Travatan® family is #2 prostaglandin drug for 20.0% +2.2 Global Glaucoma based upon global market share data. 18.6% Glaucoma Share Point 16.4% Gain 16.0% 12.0% 8.0% +2.7 global share 4.0% points 0.0% Q2 06 Q3 06 Q4 06 Q1 07
Slide 9: Glaucoma growth in Japan
Glaucoma growth in Japan TRAVATANZ™ Share of Japanese Prostaglandin Market 7.0% 6.5% 6.0% 5.0% Japan Launch of 4.0% TRAVATANZ ™ 3.0% 2.0% 1.0% 0.0% Oct-07 Nov-07 Dec-07 Jan-08 Feb-08 Mar-08 Apr-08 May-08 Jun-08 Source: IMS 9
Slide 10: Patanol Family Continues as Market Leader
Patanol® Family Continues as Market Leader U.S. Patanol® Family Market Share Growth Japan Patanol® Unit Market Share Growth 80.0 2 5 .0 % 79.0 22.3% 78.0 Market Share +4.2 growth since PY 77.0 2 0 .0 % 18.0% 76.0 75.0 15 .0 % 13.9% 74.0 73.0 +6.2 72.0 10 .0 % 71.0 70.0 5 .0 % 69.0 68.0 67.0 0 .0 % J
Slide 11: Surgical Sales
Surgical Sales Q2 2008 Sales by Product Line 2nd Qtr $850 . 6 % 13.1% +21 cy* + Consumer $800 e n $221.4 Curr t stan n Pharma $750 Co $768.7 $745.1 $700 Surgical $768.7 $650 44.3% $600 $632.4 $550 Q2 2007 Q2 2008 * Constant currency sales growth is a non-GAAP measure presented to give investors a be
Slide 12: Positive Phaco Machine Share Growth
Positive Phaco Machine Share Growth 80% U.S. Phaco Machine Market Share as of Q1 2008 70% 65.6% 60% 59.0% 50% 40% 30% 20.3 19.9 18.2 20% 15.9 10% 0% Q4 2006 Q1 2007 Q2 2007 Q3 2007 Q4 2007 Q1 2008 AMO Bausch & Lomb Alcon Source: Q1 2008 Market Scope 12
Slide 13: Continued Alcon IOL Share Gains
Continued Alcon IOL Share Gains Alcon U.S. IOL Unit Share U.S. Aspheric Monofocal Unit Share 65% 100.0% 61.4% 90.0% 80.0% 60% 70.0% 60.0% 55% 52.8% 50.0% 40.0% 30.0% 58.4 58.9 61.1 63.3 64.2 50% 20.0% 10.0% 45% 0.0% Q1 07 Q2 07 Q3 07 Q4 07 Q1 08 2005 2006 2007 2008 YTD Alcon AMO Bausch and Lomb Sour
Slide 14: Advanced Technology IOL Sales Trend
Advanced Technology IOL Sales Trend $60 $50.9 $50 Dollars in Millions $40 $30 $20 $10 $- Q1 05 Q2 05 Q3 05 Q4 05 Q1 06 Q2 06 Q3 06 Q4 06 Q1 07 Q2 07 Q3 07 Q4 07 Q1 08 Q2 08 Toric Toric CMS ReSTOR® IOL Timeline Launch Decision Aspheric Launch Source: Company Analysis 14
Slide 15: Consumer Eye Care Sales
Consumer Eye Care Sales Q2 2008 Sales by Product Line 2nd Qtr $250 .8 % +2.2% +7 Consumer $221.4 cy* n e Curr 12.8% t stan n $225 Co Pharma $745.1 $221.4 Surgical $768.7 $200 $205.3 $175 Q2 2007 Q2 2008 * Constant currency sales growth is a non-GAAP measure presented to give investors a better compa
Slide 16: Successful Growth in the Optometric Channel
Successful Growth in the Optometric Channel 2007 2008 YTD Consumer Products Market Market Share Share OPTI-FREE® EXPRESS®/ RepleniSH® (Branded) 49.0% 51.8% Systane® 15.0 16.8 ICAPS® 19.7 20.0 Source: Nielsen Consumer Data 2007 2008 YTD Pharmaceutical Products Market Market Share Share Patanol® / Pat
Slide 17: Financial Review
Financial Review Rick Croarkin Senior Vice President, Finance and Chief Financial Officer 17
Slide 18: Q2 Gross Profit
Q2 Gross Profit Q2 YTD $1,400 $2,500 +18.1% +17.5% $2,458.8 $2,400 $1,300 $1,320.7 $2,300 (dollars in millions) (dollars in millions) $1,200 $2,200 $2,100 $1,100 $1,118.2 $2,091.9 $2,000 $1,000 $1,900 Q2 2007 Q2 2008 Q2 YTD 2007 Q2 YTD 2008 % of Sales 76.0% 76.1% 74.9% 75.2% YTD 2007 impacted by ref
Slide 19: Q2 Operating Income
Q2 Operating Income Q2 YTD $700 $1,400 +20.3% +21.9% $600 $645.6 $1,200 $500 $1,000 $1,145.7 $536.5 (dollars in millions) (dollars in millions) $400 $800 $939.6 $300 $600 $200 $400 $100 $200 $0 $0 Q2 2007 Q2 2008 Q2 YTD 2007 Q2 YTD 2008 % of Sales 36.5% 37.2% 33.6% 35.0% YTD 2007 impacted by refract
Slide 20: Q2 Net Earnings
Q2 Net Earnings Q2 YTD $600 $1,200 +26.3% $566.4 +25.3% $500 $1,000 $995.8 $400 $448.4 $800 (dollars in millions) (dollars in millions) $794.6 $300 $600 $200 $400 $100 $200 $0 $0 Q2 2007 Q2 2008 Q2 YTD 2007 Q2 YTD 2008 % of Sales 30.5% 32.6% 28.4% 30.4% YTD 2007 impacted by refractive impairment Hig
Slide 21: Q2 Diluted EPS
Q2 Diluted EPS Q2 YTD +27.0% +26.0% $2.00 $3.50 $1.88 $3.00 $3.30 $1.50 $2.50 $1.48 $2.62 $2.00 $1.00 $1.50 $1.00 $0.50 $0.50 $0.00 $0.00 Q2 2007 Q2 2008 Q2 YTD 2007 Q2 YTD 2008 21
Slide 22: Cash Flows Analysis
Cash Flows Analysis Cash Flows from Operations $1,200 $1,072.0 2008 Highlights $1,000 • Net earnings improvement $867.5* • Focus to translate earnings (dollars in millions) $800 growth to cash flow increase • 2007 included reduction from $600 $520.8 investment in trading securities Trading Securitie
Slide 23: 2008 Full Year Financial Guidance Revision
2008 Full Year Financial Guidance Revision • Sales range of $6,460 to $6,510 million • Diluted earnings per share range of $6.48 to $6.54 • Includes costs to establish Swiss Shared Service and Marketing Centers and to integrate refractive operations 23
Slide 24: Alcon
Alcon
Slide 25: Non-GAAP Constant Currency Reconciliation
Non-GAAP Constant Currency Reconciliation Q2 Constant Q2 GAAP Exchange (dollars in millions) Currency Growth Rate Rate Changes Growth Rate Global Sales 17.9% (6.7) 11.2% Pharmaceutical 17.6% (5.5) 12.1% Surgical 21.6 (8.5) 13.1 Consumer 7.8 (5.6) 2.2 United States 7.0% -- 7.0% Developed Internationa